FYB Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Low-leverage Balance SheetA structurally low-leverage position gives Formycon financial flexibility to fund development and navigate biotech cycles without urgent refinancing. This supports sustained R&D investment, partnership talks and absorbs episodic losses, preserving strategic optionality over months.
Operating Cash Flow RecoveryA shift to positive operating cash flow indicates improving core operational performance and greater internal funding capacity for programs. Over a multi-month horizon this reduces reliance on external financing and supports ongoing development spend and partner milestone delivery.
Partner-driven Commercial ModelA business model centered on licensing, royalties and partner commercialization limits fixed selling costs and spreads commercialization risk. Durable revenue optionality from milestones, royalties and profit shares aligns incentives and enables scaling without building a global salesforce.
Bears Say
Sustained Revenue DeclineConsecutive revenue contractions weaken the base for partner royalties and milestone economics, reducing cash inflows available for R&D and operations. If this structural decline continues over months it undermines operating leverage and puts pressure on contract renegotiations.
Deep Negative Free Cash FlowPersistently negative free cash flow signals that operating inflows don't cover investment and working capital needs, creating a funding gap. Over a medium-term horizon this raises the probability of external financing, partner prepayments or dilution, stressing long-term stability.
Profitability VolatilityLarge swings between profit and loss make forecasting cash generation and partner payouts unreliable. Structural earnings volatility can erode equity, complicate long-term planning and weaken negotiating leverage with partners and suppliers over the coming months.
Formycon AG News
FYB FAQ
What was Formycon AG’s price range in the past 12 months?
Currently, no data Available
What is Formycon AG’s market cap?
Formycon AG’s market cap is CHF317.53M.
When is Formycon AG’s upcoming earnings report date?
Formycon AG’s upcoming earnings report date is Nov 12, 2026 which is in 91 days.
How were Formycon AG’s earnings last quarter?
Formycon AG released its earnings results on Aug 12, 2026. The company reported -CHF0.778 earnings per share for the quarter, missing the consensus estimate of -CHF0.131 by -CHF0.647.
Is Formycon AG overvalued?
According to Wall Street analysts Formycon AG’s price is currently Undervalued.
Does Formycon AG pay dividends?
Formycon AG does not currently pay dividends.
What is Formycon AG’s EPS estimate?
Formycon AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Formycon AG have?
Formycon AG has 17,672,928 shares outstanding.
What happened to Formycon AG’s price movement after its last earnings report?
Formycon AG reported an EPS of -CHF0.778 in its last earnings report, missing expectations of -CHF0.131. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Formycon AG?
Currently, no hedge funds are holding shares in CH:FYB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Formycon AG Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.19%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.17%
Trailing 12-Months
Company Description
Formycon AG
Headquartered in Planegg, Germany, Formycon AG, founded in 1999 and formerly known as Nanohale AG until 2012, specializes in the development and commercialization of biosimilar medications. Its robust product pipeline includes FYB201, a biosimilar equivalent to Lucentis, which is intended for the treatment of neovascular age-related macular degeneration and other severe eye conditions. The company is also progressing with FYB202, a biosimilar of Stelara, currently undergoing Phase III clinical trials for various inflammatory diseases, including moderate to severe psoriasis, Crohn's disease, and ulcerative colitis. Additionally, FYB203, a biosimilar candidate for Eylea, is in Phase III clinical trials, aiming to address similar ocular diseases like neovascular age-related macular degeneration. Further endeavors include the development of FYB206 and FYB207, with the latter being an antiviral treatment for COVID-19. To ensure the stability of its numerous drug candidates, Formycon AG maintains a collaborative agreement with Leukocare AG.
FYB Stock 12 Month Forecast
Average Price Target
―B.R.A.I.N. Biotechnology Research and Information Network
―
co.don AG
―
Medigene
―
Heidelberg Pharma AG
―
MagForce AG
―